Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $11.64

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned a consensus recommendation of “Buy” from the thirteen analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $11.6364.

Several analysts have recently issued reports on the company. Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Needham & Company LLC upped their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Finally, Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, April 6th.

Taysha Gene Therapies Stock Down 1.3%

Shares of NASDAQ:TSHA opened at $5.43 on Thursday. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 52-week low of $2.25 and a 52-week high of $7.30. The stock’s fifty day simple moving average is $5.67 and its 200-day simple moving average is $5.14. The company has a market capitalization of $1.56 billion, a P/E ratio of -14.29 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). As a group, equities research analysts forecast that Taysha Gene Therapies will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors have recently added to or reduced their stakes in the business. Marex Group plc acquired a new position in Taysha Gene Therapies in the second quarter valued at $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the second quarter valued at $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies in the third quarter valued at $40,000. Tower Research Capital LLC TRC increased its stake in Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after purchasing an additional 10,742 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.